General Motors
BP
Ford Motor Company
AstraZeneca
DaimlerChrysler
CNN
General Electric
US Senate
Credit Suisse First Boston
Volkswagen
Siemens
Philip Morris
Bloomberg
Verizon
General Motors
AT&T
FIAT
Nestle
General Dynamics
Hewlett Packard
Philips
ABN Amro
US Department of Defense
UBS Warburg
Merrill Lynch
New York Stock Exchange
AstraZeneca
The Economist
France Telecom
Boeing
Lafarge
Safeway
People's Republic of China's
Ministry of Agriculture
Lloyds
Nordea
Tesco
Pfizer
Philips
Sybase
Sprint
New York Life Insurance
Canon USA
Royal & SunAlliance
Macmillan Publishing
Lloyds
Novell
Ericsson
EDS
Philip Morris International
AT&T
Royal & SunAlliance
HM Revenue & Customs
Novartis
Credit Lyonnais
The McGraw-Hill Companies
Sun Microsystems
British American Tobacco
Norsk Hydro
US State Department
AT&T
AstraZeneca
Vodafone Omnitel
Skanska
BP
BAE Systems
AstraZeneca
Philips
Hewlett Packard
Kodak
The Royal Mail Group
Henkel
Nestle
BP
Bank of Montreal
Danske Bank
BMW
Kronos Corporation
Fujitsu Technology Services
Zurich Financial Services
AstraZeneca
Halliburton
BBC
UK Department of Trade & Industry
Siemens
US State Department
Blue Cross/Blue Shield of Massachusetts
3
T-Mobile
Channel 4 Corporation
VHA
Burges Salmon
Motorola
British Telecom
Ferrari
Deloitte & Touche
US Department of Commerce
3
3
PA Consulting
3
US Army
UK Department of Trade & Industry
EMC Corporation
US Department of Commerce
Encana Corporation
IEEE
Philips
Hewitt Associates LLC
HEALTHvision
Nestle
AstraZeneca
Paramount
Lexmark
US Department of Defense
JD Edwards
Ingersoll-Rand
Sun Microsystems
PricewaterhouseCoopers
Vodafone Omnitel
Nomura
US State Department
Reed Elsevier
Credit Lyonnais
Dow Chemical Company
General Motors
Siemens Power Generation
Texas Instruments
Henkel
Ericsson
Forrester Research
McData
Wall Street Journal
Hewlett Packard
Lloyds
NASA
SCA
Reuters
Swiss Army
ITN
UK Department of Trade & Industry
IBM NICA
Forbes.com
Nissan North America, Inc.
Toyota Motor
The McGraw-Hill Companies
Fox Sports
Society of Petroleum Engineers
US Department of Energy
European Commission
Telecom Italia
Harrah's
Siemens
MOL
AXA
Ingersoll-Rand
BP
Sybase
Napster
Oracle
AstraZeneca
ABN Amro
BBC
Compuware
Olympus
ARM
Taylor & Francis
Sun Microsystems
Federal Express
Nissan Motor
US State Department
Milward Brown Precis
3
Federal Government of Canada
UK Home Office
HM Revenue & Customs
Lloyds
3
Harvard Business School
Britvic Softdrinks
General Motors
MOL
Macmillan Publishing
Allianz Life Insurance Co
Swiss Army
Ericsson
AstraZeneca
Parliament of Singapore
3
VMS
Singapore Police Force
Nestle
Sony Music
GSA Advantage!
BBC
T-Mobile
Kaiser Permanente
Stanford Business School
Johns Hopkins
Wachovia
General Electric
Nestle
Standard Life Insurance
Raytheon
Commerzbank
Britvic Softdrinks
Allstate Insurance
Danske Bank
State of Washington
Napa Valley County
Texas Department of Transportation
General Motors
Sun Microsystems
American HomePatient
TIBCO
Pfizer
New York Life Insurance
Sharper Image
US Department of Defense
Xerox
America Online
Lockheed Northrop Grumman
Philips
Dow Chemical Company
Draeger Medical
Sutter Health
Kenyan AIDS Clinic
University of Washington
State of Minnesota
World Wildlife Fund
Autonomy Group Customers
 
News
Events
RSS Feeds
Press Release Archives
For Financial News, please see the Investors section of the website.

News CARDIFF NAMED 'FAST ... | ASTRAZENECA SELECTS ... | VERITY NAMES TODD K....
Press Release
Related Events
Related Case Studies
Related Resources

AstraZeneca Selects Autonomy's Technology To Assist In Global Drug Development And Product Delivery

All areas of the company - from R&D to business management to benefit from automated knowledge management system

CAMBRIDGE, England, 10th August 2000 - Autonomy today announced that AstraZeneca, the major international pharmaceutical company known for its research and products in many critical disease areas, including oncology, gastrointestinal and cardiovascular diseases, has adopted Autonomy's Portal-in-a-Box™ product to automatically manage and personalise information to help in the fight against chronic illnesses.

Using Portal-in-a-Box™, AstraZeneca will be able to automatically categorise information from a wide range of internal and external sources - the Web, the Intranet, internal documents and e-mails - and deliver it to the appropriate users in real time, as the information becomes available.

The ability to manage information automatically in this way enables users to cut through the growing volume of unstructured information - Web pages, Intranet pages, e-mails, word processing files - that characterise today's businesses. The volume of information on the Web alone is doubling every three months; within enterprises, one in five companies has had to increase its network resources by 75% or more to manage its growing corporate information.

At the heart of Autonomy's software is a pattern recognition technology, which has the ability to analyse a piece of text and identify the main ideas. This enables the software to then determine how the text should be categorised, who should see it, what other relevant material it should be linked to, and how it should be tagged - which all happens automatically.

Duncan Fyfe, Director of Informatics, Product Strategy and Licensing at AstraZeneca, commented: "The growing volume of unstructured information in any enterprise is threatening to overwhelm the users of that information. By using Autonomy, we can ensure that the right material reaches the right person at the right time. This in turn means that our staff are better informed, our research decisions better supported, and the costs typically associated with managing information significantly reduced."

Dr. Mike Lynch, Group CEO of Autonomy, said: "Astra Zeneca has recognised that its need to manage vast amounts of information and tailor it to individual users cannot be addressed using only manual or keyword-based approaches. Autonomy gives AstraZeneca the edge by enabling it to manage its information automatically, on the basis of content. This makes for more effective knowledge management and translates ultimately into more rapid advances in research."

About Autonomy Corporation plc

Autonomy's technology powers large-scale, personalised systems for the Enterprise, Internet and other Digital domains. Because of its ability to analyse any piece of text (independent of the document's language) and identify and rank the main ideas, Autonomy can automate a broad range of otherwise labor intensive tasks. These range from categorising information by subject matter, to inserting hypertext links to related material, to profiling users based on the ideas in the text they read or write, to delivering information to those most likely to be interested.

Autonomy (EASDAQ/NASDAQ: AUTN) was founded in 1996 and has offices in Boston, Chicago, Dallas, San Francisco, New York, and Washington, D.C. in the United States, as well as offices in Amsterdam, Brussels, Cambridge, England, Frankfurt, Milan, Paris, Oslo and Sydney.

Among its 200-plus customers are Alcatel, Associated Press, Barclays Bank, British Aerospace, Clorox, News Corp., Lucent Technologies, Merrill Lynch, SF Gate, Reuters Semi-tech, The Royal Mail, Unilever, and the United States Department of Defense. In addition, several software companies are licensing Autonomy's technology to add intelligence to their online publishing, knowledge management, email routing and document management applications, including Aeneid, Brio, CoreChange, Delano, Filenet, FutureTense, Hyperwave, Insight, Intranet Solutions, Intraspect, KnowledgeTrack, Global Recall, Nexor, Novient, OpenMarket, Sagemaker, Sybase, Verge and Vignette.

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and the supply of healthcare services. It is one of the top five pharmaceutical companies in the world with healthcare sales of over $15 billion and leading positions in sales of gastrointestinal, oncology, anaesthesia including pain management, cardiovascular, central nervous system (CNS) and respiratory products.

Note:

With the exception of historical information, the matters set forth in this news release are forward-looking statements that involve risks and uncertainties. A number of important factors could cause actual results to differ materially from those in the forward-looking statements. These factors include, among others, dependence on core technology; limited operating history; fluctuations in quarterly results; dependence on new product development; rapid technological and market change; reliance on sales by others; management of growth; dependence on key personnel; rapid expansion; technology risks; volatility of stock price; growth of the Internet; financial risk management; and future growth subject to risks. These factors and other factors which could cause actual results to differ materially are also discussed in the company's filings with the United States Securities and Exchange Commission, including Autonomy's Registration Statement on Form F-1, File no. 333-11804.

For more information, please contact:
AUTONOMY CORPORATION plc
Dr. Mike Lynch, Managing Director and CEO
Ralph Harms, Chief Financial Officer
Dominic Johnson, Marketing Director
Tel: 01223 421220

This is a selection of our forthcoming events, please visit our seminars page for more information.

Automatic Hyperlinks provided by IDOL Server 7

This is a small selection of the Autonomy case studies available, please visit our publications site at http://publications.autonomy.com/ for more information.

Automatic Hyperlinks provided by IDOL Server 7

+1 415 243 9955

Company
Technology
Functionality
Products
Solutions
Services
Customers
Partners
News & Events